Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05291247
Other study ID # FCRE-210505
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 22, 2022
Est. completion date October 2024

Study information

Verified date July 2023
Source FCRE (Foundation for Cardiovascular Research and Education)
Contact Annelena Held-Wehmöller, PhD
Phone +4915785128140
Email shockwave_des@fcre.eu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The objective of this clinical investigation is to evaluate, in a controlled setting, the 12 months safety and efficacy of the combination of Shockwave Intravascular Lithotripsy and a polymer coated Drug Eluting Stent device, for PACSS 3 and PACSS 4 calcified femoropopliteal disease.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date October 2024
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender All
Age group 21 Years to 85 Years
Eligibility Inclusion Criteria: - Subject must be between 21 and 85 years old - Clinical diagnosis of symptomatic peripheral artery disease, defined by Rutherford Becker Classification score 3-5 - Willing to comply with the specified follow-up evaluation - Written informed consent prior to any study procedures - Stenotic, restenotic after PTA or occlusive lesion(s) located in the native Superficial Femoral Artery (SFA) and/or proximal Popliteal Artery (PPA): 1. Degree of stenosis = 70% by visual agiographic assessment 2. Vessel diameter = 4 and = 6 mm 3. Total lesion length (or series of lesions) = 30 mm and 210 mm (Note: Lesion segment(s) must be filly covered with one or two overlapping DES stent (s) be fully covered with one or two overlapping DES stent(s) 4. Target lesion located at least three centimeters above the inferior edge of the femur - Severity of calcification PACSS 3-4 - Patent infrapopliteal and popliteal artery; i.e. single vessel runoff or better with at least one of three vessels patent (>50% stenosis) to the ankle or foot with no planned intervention. - Study entry after successful target lesion crossing of the guidewire (guidewire located intraluminally or subintimally); Both crossing devices as well as retrograde recanalization can be used. - Non-target lesion interventions to restore adequate blood flow, in the same index procedure are allowed. This intervention must be prior to the treatment of the study lesion and should be completed successfully. Exclusion Criteria: - Not treated ipsilateral significant (>50%) stenosis of the iliac arteries - Non severely calcified disease (absence of calcification, PACSS 1, PACSS 2) - Significant (>50%) stenosis of all infrapopliteal arteries, no patent artery to the foot - Angiographic evidence of thrombus within the target vessel - Thrombolysis within 72 hours prior to the index procedure - Previously stented target lesion / vessel - Subjects who have undergone prior surgery of the target lesion SFA/PPA to treat atherosclerotic disease - Bypass Anastomosis stenosis - Concomitant hepatic insufficiency, thrombophlebitis, deep venous thrombus, coagulation disorder or receiving immunosuppressant therapy - Recent MI or stroke <30 days prior to the index procedure - Life expectancy less than 24 months - Known or suspected active infection at the time of the index procedure - Known or suspected major allergies or contraindications to aspirin, clopidogrel bisulfate (Plavix) and ticlopidine (Ticlid), heparin, or contrast agent - Any significant medical condition which, in the investigator's opinion, may interfere with the subject's optimalparticipation in the study - The subject is currently participating in another drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study - Female subjects pregnant, breastfeeding, of childbearing potential who are planning to become pregnant in the next 5 years. - End-stage-renal disease - Presence of Severe Ischemic Ulcers or frank gangrene (Rutherford class 6).

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Peripheral lithotripsy system (Shockwave Medical)
The combination of Shockwave Intravascular Lithotripsy and a polymer coated Drug Eluting Stent device for calcified femoropopliteal disease.

Locations

Country Name City State
Germany Klinikum Hochsauerland Arnsberg
Germany University Hospital Essen Essen
Germany University Hospital Eppendorf Hamburg
Germany SRH Klinikum Karlsbad-Langensteinbach Karlsbad
Germany St. Marien Hospital Lünen
Germany University Hospital LMU Munich Munich

Sponsors (1)

Lead Sponsor Collaborator
Dr. Sabrina Overhagen

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Patency Defined as a target lesion without a hemodynamically significant stenosis on duplex ultrasound (>50%, systolic velocity ratio no greater than 2.4) and without Target Lesion Revascularization (TLR) 12 months
Primary Procedural success: Defined as technical success and completion of the procedure without complications , meaning successful treatment of the vessels (technical success) in the absence of:
vessel rupture or perforation that require an intervention
need for emergency surgical revascularization of target limb
symptomatic thrombus or distal emboli that require surgical, mechanical, or pharmacologic means to improve flow and extend hospitalization
unplanned above the ankle amputation
major adverse cardiovascular events (defined as composite of total death, myocardial infarction, coronary revascularization and stroke).
30 days post procedure
Secondary Primary Patency Defined as a target lesion without a hemodynamically significant stenosis on duplex ultrasound (>50 systolic velocity ratio no greater than 2,4) and without Target Lesion Revascularization (TLR) 6 months
Secondary Target Lesion Revascularization (TLR) Defined as the need for target lesion revascularization after index procedure. 6- and 12-months
Secondary Secondary Patency Rate Defined as restored flow in the treated segment after occlusion or restenosis. 6- and 12-months
Secondary Amputation-free Survival rate Defined as the time until a major amputation of the index limb and/or death of any cause, whichever occurred first. 6- and 12-months
Secondary Major Amputation Rate Defined as any aboveankle amputation. 6- and 12-months
Secondary Clinical Success Defined as an improvement of the Rutherford Becker Classification of one class or more, as compared to the preprocedure Rutherford Becker Classification. 6- and 12-months
Secondary Absence of Major Adverse Events (MAE) Acute Coronary Syndrome, Stroke, Death, Major Amputation or TLR. 6- and 12-months
See also
  Status Clinical Trial Phase
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Active, not recruiting NCT03987061 - MOTIV Bioresorbable Scaffold in BTK Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Active, not recruiting NCT04677725 - NEtwork to Control ATherothrombosis (NEAT Registry)
Recruiting NCT05961943 - RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients N/A
Recruiting NCT06047002 - Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
Completed NCT03185052 - Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach N/A
Recruiting NCT05992896 - A Study of Loco-Regional Liposomal Bupivacaine Injection Phase 4
Completed NCT04635501 - AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial N/A
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Withdrawn NCT03994185 - The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease N/A
Withdrawn NCT03538392 - Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
Recruiting NCT02915796 - Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty Phase 1
Active, not recruiting NCT02900924 - Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
Completed NCT02901847 - To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities. N/A
Withdrawn NCT02126540 - Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries N/A
Not yet recruiting NCT02455726 - Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease N/A
Not yet recruiting NCT02387450 - Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication Phase 2/Phase 3
Completed NCT02384980 - Saving Life and Limb: FES for the Elderly With PAD Phase 1